FDA awards Orphan Drug status to Lakefront's gamgertamig in pemphigus

Lakefront Biotherapeutics has announced that the US Food and Drug Administration has granted Orphan Drug Designation to gamgertamig for the treatment of pemphigus, a rare and potentially life-threatening autoantibody-driven skin disease. The Belgian-American biotech, listed on both Euronext and NASDAQ, said the designation adds to existing FDA Orphan Drug and Fast Track statuses the drug already holds for autoimmune haemolytic anaemia and immune thrombocytopenia.

Gamgertamig is a BCMAxCD3 bispecific T cell engager designed to deplete the antibody-secreting B cells that drive autoantibody-mediated conditions. It is being co-developed with Gilead Sciences and was originally in-licensed from Keymed Biosciences, which retains rights for Greater China. Lakefront describes gamgertamig as a potential first-in-class and best-in-class candidate in its therapeutic category.

Clinical programme

Two Phase 1b studies are currently enrolling. One is assessing gamgertamig in autoimmune cytopenias, including ITP and AIHA, at sites in Australia and the United States. The second covers seropositive autoimmune diseases, including idiopathic inflammatory myositis, Sjogren's disease, pemphigus vulgaris, and pemphigus foliaceus, across Australia, New Zealand, the Czech Republic, and Japan. Lakefront said it expects to initiate proof-of-concept basket studies in additional autoimmune indications and anticipates expansion of the clinical programme in 2027.

Eric Hedrick, Chief Medical Officer at Lakefront, described pemphigus as a "debilitating and potentially life-threatening autoantibody-driven disease" and said the company believes gamgertamig has the potential to be transformative across autoimmune conditions. The phrase "transformative medicine" has been noted by this publication as promotional language and should be read with that in mind.

Market context and regulatory landscape

Orphan Drug Designation confers several commercially significant benefits in the United States, including seven years of market exclusivity upon approval, exemption from certain FDA user fees, and eligibility for tax credits on clinical trial costs. For a company at Lakefront's stage, this represents meaningful de-risking of the regulatory path.

Pemphigus is a rare autoimmune blistering disorder affecting an estimated 30,000 to 40,000 people in the United States. Rituximab, the anti-CD20 monoclonal antibody, is currently the standard of care for moderate-to-severe disease. Several companies are pursuing next-generation approaches, including neonatal Fc receptor inhibitors, which reduce circulating autoantibody levels without directly targeting B cells, and other T cell engager platforms. Gamgertamig's BCMA-targeting strategy is differentiated in that it aims to deplete long-lived plasma cells, which are thought to sustain pathogenic autoantibody production even after B cell depletion.

The Gilead collaboration gives Lakefront considerable operational and financial backing as it expands the basket-study approach. Registrational studies are anticipated to begin in 2027, meaning meaningful efficacy data for pemphigus specifically remains some years away. Investors will track Phase 1b readouts from both running studies as the earliest signal of tolerability and target engagement in this broadening indication set.